Skip to main content
TipRanks
Go Ultimate75% OFF

Klaria Pharma Holding AB (KLAR) AI Stock Analysis

7 Followers
SE:KLAR

Klaria Pharma Holding AB

(Nasdaq OMX AB:KLAR)

Select Model
Rating:37Underperform
Price Target:SEK 0.51â–²(1.60% Upside)
Action:reiterated
Date:10/11/26

The overall score of 37 reflects a company in severe financial distress with a high risk of failure. The most significant factor is the critically weak financial performance, marked by a near-total revenue collapse, massive and accelerating cash burn, and a negative equity position that threatens its viability. This is compounded by a bearish technical trend, with the stock in a sustained downtrend across all timeframes, and a negative P/E ratio that confirms a complete lack of profitability. The company's survival is in serious doubt without immediate and transformative capital infusion.

Positive Factors
Buccal film platformKlaria has a defined technology platform rather than an undifferentiated drug-development approach. Applying buccal thin-film delivery across therapeutic areas could support multiple product programs and create reusable development expertise if candidates progress successfully.
Negative Factors
Minimal revenue and persistent lossesThe company has not yet demonstrated a sustainable commercial earnings base: TTM revenue is minimal while losses remain very large and margins are sharply negative. Persistent losses reduce internal funding capacity and leave future value dependent on successful product progress or external financing.

Klaria Pharma Holding AB (KLAR) vs. iShares MSCI Sweden ETF (EWD)

-25%0%25%50%75%100%125%SE:KLAR-10.71%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 122.99M
Dividend Yield
―
Average Volume (3M)
853.89K
Price to Earnings (P/E)
-3.0
Beta (1Y)
1.74
Revenue Growth
-99.01%
EPS Growth
38.00%
Country
Sweden
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Klaria Pharma Holding AB Business Overview & Revenue Model

Company Description

Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. W...

How the Company Makes Money

Klaria Pharma Holding AB’s primary path to monetization is typical of early-stage/specialty pharma development companies: progressing product candidates and its drug-delivery platform toward partnering and/or commercialization. Key expected revenue s...

Klaria Pharma Holding AB Financial Statement Overview

Summary

Financial health is critically weak. Revenue has collapsed to near zero (116k SEK TTM), net losses are massive and growing (TTM net margin -334%), and the balance sheet shows deeply negative equity (-33.6M SEK). The most severe risk is an accelerating cash burn, with TTM operating cash flow at -48.5M SEK, making the business entirely reliant on external funding and raising substantial doubt about its viability as a going concern.

Income Statement

8Very Negative

Balance Sheet

5Very Negative

Cash Flow

3Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue116.00K9.00M2.25M8.45M5.87M6.11M
Gross Profit2.84M-2.23M2.25M8.45M5.87M-4.85M
EBITDA-23.20M-9.20M-19.99M-20.81M-44.80M-39.41M
Net Income-38.73M-38.90M-47.75M-35.78M-63.77M-53.53M
Balance Sheet
Total Assets37.47M40.77M57.27M72.95M120.27M118.31M
Cash, Cash Equivalents and Short-Term Investments8.47M342.00K598.00K1.25M16.76M25.49M
Total Debt9.70M023.07M18.93M17.09M31.72M
Total Liabilities71.08M44.65M53.96M31.81M44.19M48.89M
Stockholders Equity-33.62M-3.88M3.31M41.13M76.08M69.41M
Cash Flow
Free Cash Flow-13.48M-35.04M-11.94M-3.37M-49.77M-24.80M
Operating Cash Flow-48.51M-35.04M-11.94M-9.06M-49.73M-24.80M
Investing Cash Flow0000-42.00K0
Financing Cash Flow55.01M34.78M11.27M-6.46M41.06M19.04M

Klaria Pharma Holding AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.50

Price Trends

50DMA0.55Negative
100DMA0.70Negative
200DMA0.78Negative

Market Momentum

MACD-0.02Negative
RSI39.96Neutral
STOCH17.52Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KLAR, the sentiment is Negative. The current price of 0.50 is below the 20-day moving average (MA) of 0.52, below the 50-day MA of 0.55, and below the 200-day MA of 0.78, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.96 is Neutral, neither overbought nor oversold. The STOCH value of 17.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:KLAR.

Klaria Pharma Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:KLAR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ALZCURSE:ALZCUR51NeutralSEK 879.79M10.63105.09%―――
SE:ISOFOLSE:ISOFOL48NeutralSEK 339.08M-5.64-58.68%――35.02%
SE:ELICSE:ELIC47NeutralSEK 166.84M-7.07-56.09%――14.10%
SE:XBRANESE:XBRANE46NeutralSEK 219.45M-5.89-11.52%―-38.80%-120.18%
SE:KLARSE:KLAR37UnderperformSEK 122.99M-3.00289.25%―-99.01%38.00%
SE:IRLAB.ASE:IRLAB.A37UnderperformSEK 126.41M-1.69-75.46%―-21.20%68.24%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%SE:KLARSE:ALZCURSE:XBRANESE:ISOFOLSE:ELICSE:IRLAB.ADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:KLAR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:KLARKlaria Pharma Holding AB0.50-0.01-1.57%
SE:ALZCURAlzeCure Pharma AB6.384.58253.66%
SE:XBRANEXbrane Biopharma AB10.650.706.98%
SE:ISOFOLIsofol Medical AB1.060.3651.36%
SE:ELICElicera Therapeutics AB2.50-2.78-52.66%
SE:IRLAB.AIRLAB Therapeutics AB Class A0.85-1.39-62.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 11, 2026